University of California San Francisco | About UCSF | UCSF Benioff Children's Hospital San Francisco
Search Site | Find a Doctor

Scott Zamvil, M.D.

Neurologist

Dr. Scott Zamvil is a neurologist who specializes in the treatment of multiple sclerosis. He joined UCSF Medical Center in 1988. Prior to joining UCSF, he was a neurologist at Brigham and Women's Hospital in Boston, Mass. For his work in multiple sclerosis, he was named a Harry Weaver Neuroscience Scholar by the National Multiple Sclerosis Society in 1994. He has received funding for research from the National Multiple Sclerosis Society, National Institutes of Health, Wadsworth Foundation and Maisin Foundation. His research explores the role of different antigen presenting cells in the activation of T cells and the possible therapeutic uses of statins, or cholesterol-lowering drugs, in MS.

Zamvil earned his medical degree and doctorate in medical microbiology from Stanford University. He completed a residency in internal medicine at Stanford and a residency in neurology at Brigham and Women's Hospital.

Clinics

Multiple Sclerosis Center
1500 Owens St., Suite 320
San Francisco, CA 94158
Phone: (415) 353-2069
Fax: (415) 353-2633

Hours: Monday to Friday
7:30 a.m. – 6:00 p.m.

Conditions & Treatments

More about Scott Zamvil

Education

Stanford University School of Medicine 1988

Residencies

Stanford University School of Medicine, Internal Medicine
Brigham and Women's Hospital, Neurology

Selected Research and Publications

  1. Onizawa M, Oshima S, Schulze-Topphoff U, Oses-Prieto JA, Lu T, Tavares R, Prodhomme T, Duong B, Whang MI, Advincula R, Agelidis A, Barrera J, Wu H, Burlingame A, Malynn BA, Zamvil SS, Ma A. Erratum: The ubiquitin-modifying enzyme A20 restricts ubiquitination of the kinase RIPK3 and protects cells from necroptosis. Nat Immunol. 2015 Jun 18; 16(7):785.
  2. Bennett JL, O'Connor KC, Bar-Or A, Zamvil SS, Hemmer B, Tedder TF, von Büdingen HC, Stuve O, Yeaman MR, Smith TJ, Stadelmann C. B lymphocytes in neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm. 2015 Jun; 2(3):e104.
  3. Onizawa M, Oshima S, Schulze-Topphoff U, Oses-Prieto JA, Lu T, Tavares R, Prodhomme T, Duong B, Whang MI, Advincula R, Agelidis A, Barrera J, Wu H, Burlingame A, Malynn BA, Zamvil SS, Ma A. The ubiquitin-modifying enzyme A20 restricts ubiquitination of the kinase RIPK3 and protects cells from necroptosis. Nat Immunol. 2015 Jun; 16(6):618-27.
  4. Lehmann-Horn K, Sagan SA, Bernard CC, Sobel RA, Zamvil SS. B-cell very late antigen-4 deficiency reduces leukocyte recruitment and susceptibility to central nervous system autoimmunity. Ann Neurol. 2015 May; 77(5):902-8.
  5. von Büdingen HC, Palanichamy A, Lehmann-Horn K, Michel BA, Zamvil SS. Update on the autoimmune pathology of multiple sclerosis: B-cells as disease-drivers and therapeutic targets. Eur Neurol. 2015; 73(3-4):238-46.
  6. Spencer CM, Crabtree-Hartman EC, Lehmann-Horn K, Cree BA, Zamvil SS. Reduction of CD8(+) T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate. Neurol Neuroimmunol Neuroinflamm. 2015 Jun; 2(3):e76.
  7. Zamvil SS, Slavin AJ. Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder? Neurol Neuroimmunol Neuroinflamm. 2015 Feb; 2(1):e62.
  8. Gourraud PA, Henry RG, Cree BA, Crane JC, Lizee A, Olson MP, Santaniello AV, Datta E, Zhu AH, Bevan CJ, Gelfand JM, Graves JS, Goodin DS, Green AJ, von Büdingen HC, Waubant E, Zamvil SS, Crabtree-Hartman E, Nelson S, Baranzini SE, Hauser SL. Precision medicine in chronic disease management: The multiple sclerosis BioScreen. Ann Neurol. 2014 Nov; 76(5):633-42.
  9. Shetty A, Gupta SG, Varrin-Doyer M, Weber MS, Prod'homme T, Molnarfi N, Ji N, Nelson PA, Patarroyo JC, Schulze-Topphoff U, Fogal SE, Forsthuber T, Sobel RA, Bernard CC, Slavin AJ, Zamvil SS. Immunodominant T-cell epitopes of MOG reside in its transmembrane and cytoplasmic domains in EAE. Neurol Neuroimmunol Neuroinflamm. 2014 Aug; 1(2):e22.
  10. Varrin-Doyer M, Shetty A, Spencer CM, Schulze-Topphoff U, Weber MS, Bernard CC, Forsthuber T, Cree BA, Slavin AJ, Zamvil SS. MOG transmembrane and cytoplasmic domains contain highly stimulatory T-cell epitopes in MS. Neurol Neuroimmunol Neuroinflamm. 2014 Aug; 1(2):e20.
  11. Varrin-Doyer M, Zamvil SS, Schulze-Topphoff U. Laquinimod, an up-and-coming immunomodulatory agent for treatment of multiple sclerosis. Exp Neurol. 2014 Dec; 262 Pt A:66-71.
  12. Weber MS, Prod'homme T, Youssef S, Dunn SE, Steinman L, Zamvil SS. Neither T-helper type 2 nor Foxp3+ regulatory T cells are necessary for therapeutic benefit of atorvastatin in treatment of central nervous system autoimmunity. J Neuroinflammation. 2014; 11:29.
  13. Molnarfi N, Schulze-Topphoff U, Weber MS, Patarroyo JC, Prod'homme T, Varrin-Doyer M, Shetty A, Linington C, Slavin AJ, Hidalgo J, Jenne DE, Wekerle H, Sobel RA, Bernard CC, Shlomchik MJ, Zamvil SS. MHC class II-dependent B cell APC function is required for induction of CNS autoimmunity independent of myelin-specific antibodies. J Exp Med. 2013 Dec 16; 210(13):2921-37.
  14. Brück W, Gold R, Lund BT, Oreja-Guevara C, Prat A, Spencer CM, Steinman L, Tintoré M, Vollmer TL, Weber MS, Weiner LP, Ziemssen T, Zamvil SS. Therapeutic decisions in multiple sclerosis: moving beyond efficacy. JAMA Neurol. 2013 Oct; 70(10):1315-24.
  15. Schulze-Topphoff U, Casazza S, Varrin-Doyer M, Pekarek K, Sobel RA, Hauser SL, Oksenberg JR, Zamvil SS, Baranzini SE. Tob1 plays a critical role in the activation of encephalitogenic T cells in CNS autoimmunity. J Exp Med. 2013 Jul 1; 210(7):1301-9.
  16. Hertzenberg D, Lehmann-Horn K, Kinzel S, Husterer V, Cravens PD, Kieseier BC, Hemmer B, Brück W, Zamvil SS, Stüve O, Weber MS. Developmental maturation of innate immune cell function correlates with susceptibility to central nervous system autoimmunity. Eur J Immunol. 2013 Aug; 43(8):2078-88.
  17. Cravens PD, Kieseier BC, Hussain R, Herndon E, Arellano B, Ben LH, Timmons BC, Castro-Rojas C, Hartung HP, Hemmer B, Weber MS, Zamvil SS, Stüve O. The neonatal CNS is not conducive for encephalitogenic Th1 T cells and B cells during experimental autoimmune encephalomyelitis. J Neuroinflammation. 2013; 10:67.
  18. Varrin-Doyer M, Spencer CM, Schulze-Topphoff U, Nelson PA, Stroud RM, Cree BA, Zamvil SS. Aquaporin 4-specific T cells in neuromyelitis optica exhibit a Th17 bias and recognize Clostridium ABC transporter. Ann Neurol. 2012 Jul; 72(1):53-64.
  19. Brück W, Zamvil SS. Laquinimod, a once-daily oral drug in development for the treatment of relapsing-remitting multiple sclerosis. Expert Rev Clin Pharmacol. 2012 May; 5(3):245-56.
  20. Jukkola PI, Lovett-Racke AE, Zamvil SS, Gu C. K+ channel alterations in the progression of experimental autoimmune encephalomyelitis. Neurobiol Dis. 2012 Aug; 47(2):280-93.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.